Title:
A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Indication:
Lung Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).
Indication:
Lung Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Breast Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Breast Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Breast Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Breast Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
INCMGA00012 Endo Cancer
View
Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)
Indication:
Endometrial Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ
View
Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)
Indication:
Gastric Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Gastric Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Gastric Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Gastric Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Gastric Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Hematologic
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Leukemia
Location:
Texas Oncology-Grapevine
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Leukemia
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 MRTX849 Pembro NSCLC KRAS
View
Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)
Indication:
Lung Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 Tomivosertib+Anti-PD-L1 NSCLC
View
Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)
Indication:
Lung Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C
View
Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies
Indication:
Lung Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Lung Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Lung Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Lung Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR BV in pts w/1L cHL or PTCL
View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-Grapevine
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR: Zanu in Acala intolerant B-Cell
View
Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
Indication:
Lymphomas
Location:
Texas Oncology-Grapevine
Phase: II
Title:
PH2 Brentux+CHP In Tx Naive PTCL
View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Melanoma
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Selinexor vs PC MF
View
Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)
Indication:
Myelofibrosis
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 Dara Lena Dexa (DRd) MM I
View
Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)
Indication:
Myelomas
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 VS-6766 Fak-Inhib LGSOC
View
Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph1b/2 XMT-1536 ST NaPi2b
View
Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Ovarian Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 AKT Pac vs Ova fall and Peri
View
Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
Ph2 BMS986218 + Niv combo Doce met CRPC
View
Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)
Indication:
Prostate Cancer
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 Seribantumab NRG1 Fusion+ ST
View
Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)
Indication:
Solid Tumors
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 Bren Vedo + Pembro ST prior PD-1
View
Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington South
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Bedford
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II
Title:
STAR Ph2 ZN-c3 Tumor DNA Repair CCGA
View
Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)
Indication:
Solid Tumors
Location:
Texas Oncology-Grapevine
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington Cancer Center North
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Solid Tumors
Location:
Texas Oncology-Arlington South
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Solid Tumors
Location:
Texas Oncology-Bedford
Phase: II
Title:
Ph2 TJ004309 + Atezo OC/ST
View
Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)
Indication:
Solid Tumors
Location:
Texas Oncology-Fort Worth Cancer Center
Phase: II